My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 348

    1.

    Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

    Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL.

    Arthritis Res Ther. 2005;7(3):R666-76. Epub 2005 Apr 4.

    PMID:
    15899052
    [PubMed - indexed for MEDLINE]
    Free PMC Article

    Related citations

    2.

    Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register.

    Arthritis Rheum. 2007 Jan;56(1):13-20.

    PMID:
    17195186
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    3.

    Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

    Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR.

    Ann Rheum Dis. 2009 Feb;68(2):209-15. Epub 2008 Apr 2. Review.

    PMID:
    18385277
    [PubMed - indexed for MEDLINE]
    Free PMC Article

    Related citations

    4.

    Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.

    Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL.

    Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30-3.

    PMID:
    14532145
    [PubMed - indexed for MEDLINE]
    Free PMC Article

    Related citations

    5.

    B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

    Arthritis Rheum. 2007 May;56(5):1417-23.

    PMID:
    17469098
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    6.

    Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.

    Kroesen S, Widmer AF, Tyndall A, Hasler P.

    Rheumatology (Oxford). 2003 May;42(5):617-21.

    PMID:
    12709536
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    7.

    Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

    Arthritis Rheum. 2006 Aug;54(8):2368-76.

    PMID:
    16868999
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    8.

    Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

    JAMA. 2009 Feb 18;301(7):737-44.

    PMID:
    19224750
    [PubMed - indexed for MEDLINE]

    Related citations

    9.

    Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.

    Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N.

    Ann Rheum Dis. 2009 May;68(5):648-53. Epub 2008 May 8.

    PMID:
    18467516
    [PubMed - indexed for MEDLINE]

    Related citations

    10.

    Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.

    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.

    Isr Med Assoc J. 2008 Apr;10(4):277-81.

    PMID:
    18548981
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    11.

    TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice.

    Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG.

    Ann N Y Acad Sci. 2009 Sep;1173:837-46.

    PMID:
    19758236
    [PubMed - indexed for MEDLINE]

    Related citations

    12.

    Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

    Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

    Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

    PMID:
    16705046
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    13.

    Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.

    Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF.

    Rheumatology (Oxford). 2009 Aug;48(8):906-10. Epub 2009 May 28.

    PMID:
    19478038
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    14.

    Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.

    Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

    Arthritis Rheum. 2007 May 15;57(4):679-85.

    PMID:
    17471545
    [PubMed - indexed for MEDLINE]
    Free Article

    Related citations

    15.

    Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.

    Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, Zingarelli S, Caporali R, Cattaneo R, Montecucco CM.

    Clin Exp Rheumatol. 2007 Sep-Oct;25(5):676-83.

    PMID:
    18078613
    [PubMed - indexed for MEDLINE]

    Related citations

    16.

    Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.

    Inanc N, Direskeneli H.

    Rheumatol Int. 2006 Nov;27(1):67-71. Epub 2006 Aug 2.

    PMID:
    16896990
    [PubMed - indexed for MEDLINE]

    Related citations

    17.

    Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis.

    Mayer Y, Balbir-Gurman A, Machtei EE.

    J Periodontol. 2009 Sep;80(9):1414-20.

    PMID:
    19722791
    [PubMed - indexed for MEDLINE]

    Related citations

    18.

    Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.

    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.

    J Rheumatol. 2007 Dec;34(12):2334-42. Epub 2007 Nov 1.

    PMID:
    17985409
    [PubMed - indexed for MEDLINE]

    Related citations

    19.

    Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.

    Peña-Sagredo JL, Fariñas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibañez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernández MV, Rodríguez-Gómez M, Maíz O, López R, Cobo T, Pita J, Carmona L, Gonzalez-Gay MA; BIOBADASER and EMECAR Groups.

    Clin Exp Rheumatol. 2009 Nov-Dec;27(6):920-5.

    PMID:
    20149306
    [PubMed - indexed for MEDLINE]

    Related citations

    20.

    Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.

    Lancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.

    PMID:
    19560810
    [PubMed - indexed for MEDLINE]

    Related citations

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Filter your results:

      Find related data

      Recent activity

      You are here: NCBI > Literature > PubMed
      Write to the Help Desk